GMB and Unite say 350 job cuts in R&D at Chesire facility will damage UK industry, although ABPI remains optimistic
Diabetes portfolio encourages 12 per cent increase in revenues for Denmark-based firm
Gains in diabetes division, but generics pose threat for 2012
Former Savient CEO and Lilly senior VP John Johnson replaces Gold who remains at Dendreon as executive chair
Appoints Andy Bowman and Gary Burd
Deal watch: A look at the biggest mergers and acquisitions from 2011, including Sanofi's purchase of Genzyme and J&J taking over Synthes

Currently facing a major financial crisis, Spain's healthcare system is overstretched with autonomous regions owing millions of Euros to suppliers such as the pharma industry

Therapies are facing greater scrutiny to ensure they do not carry increased risk of cardiovascular side effects

A survey of pharma companies shows they are hiring expert help to cope with the problems of an increasingly fragmented market in the UK

Patients seldom refuse therapy outright, but often show a reluctance to comply. Understanding the reasons for this is the first step to improving their treatment